Idenix Announces Public Offering of Common Stock
October 24 2005 - 6:08PM
PR Newswire (US)
CAMBRIDGE, Mass., Oct. 24 /PRNewswire-FirstCall/ -- Idenix
Pharmaceuticals, Inc. (NASDAQ:IDIX), a biopharmaceutical company
engaged in the discovery and development of drugs for the treatment
of human viral and other infectious diseases, announced today its
intention to publicly offer 7,535,913 shares of its common stock of
which 6,593,406 are being offered by the Company. Certain
stockholders of the Company are offering to sell 942,507 shares of
the Company's common stock. The selling stockholders also intend to
grant an option to the underwriters to purchase up to 1,130,387
additional shares of the Company's common stock solely to cover
over-allotments. The shares are being offered pursuant to an
effective registration statement that the Company has previously
filed with the Securities and Exchange Commission. Morgan Stanley
& Co. Incorporated is acting as the sole book runner for the
offering announced today. Bear, Stearns & Co. Inc. is acting as
co-lead manager of the offering. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be the sale of any of these securities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such jurisdiction. The offering will be made
only by means of a prospectus. A copy of the preliminary prospectus
supplement may be obtained from the Prospectus Department of Morgan
Stanley (1585 Broadway, New York, New York 10036, telephone
212-761-6775). About Idenix Idenix Pharmaceuticals, Inc. is a
biopharmaceutical company engaged in the discovery and development
of drugs for the treatment of human viral and other infectious
diseases. Idenix's current focus is on the treatment of infections
caused by hepatitis B virus, hepatitis C virus and human
immunodeficiency virus (HIV). Idenix's headquarters are located in
Cambridge, Massachusetts and it has drug discovery and development
operations in Montpellier, France and drug discovery operations in
Cagliari, Italy. Idenix Pharmaceuticals' Contacts Media: Teri
Dahlman, 617-995-9905 Investors: Amy Sullivan, 617-995-9838
DATASOURCE: Idenix Pharmaceuticals, Inc. CONTACT: Teri Dahlman,
+1-617-995-9905, or Amy Sullivan, +1-617-995-9838 both of Idenix
Web site: http://www.idenix.com/
Copyright
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024